Tumor mutational burden (TMB): a predictive biomarker for lung cancer immunotherapy response
Fred Hirsch • 24 Jan 2018
Blueprint Project update: how comparable are the results of different PD-L1 assays?
Fred Hirsch • 11 Apr 2018
Toxicity of proton therapy vs photon therapy for treatment of NSCLC with concurrent chemotherapy
Francesco Cortiula • 10 May 2022
Clinical relevance of lipid biopsy and circulating tumor cells for precision medicine
Catherine Alix-Panabieres • 12 Apr 2022